April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Cytokine Requirement, Molecular Mechanisms, and Kinetics of CD4+CD25+ T Regulatory Cells in the Establishment of Corneal Immune Privilege
Author Affiliations & Notes
  • Khrishen Cunnusamy
    Ophthalmology, UTSW Medical Center at Dallas, Dallas, Texas
  • Peter W. Chen
    Ophthalmology, UTSW Medical Center at Dallas, Dallas, Texas
  • Jerry Y. Niederkorn
    Ophthalmology, UTSW Medical Center at Dallas, Dallas, Texas
  • Footnotes
    Commercial Relationships  Khrishen Cunnusamy, None; Peter W. Chen, None; Jerry Y. Niederkorn, None
  • Footnotes
    Support  NIH grants EY007641 and EY020799 (to J.Y.N.) and an unrestricted grant from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1146. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Khrishen Cunnusamy, Peter W. Chen, Jerry Y. Niederkorn; Cytokine Requirement, Molecular Mechanisms, and Kinetics of CD4+CD25+ T Regulatory Cells in the Establishment of Corneal Immune Privilege. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1146.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : This study examined the mechanisms CD4+CD25+ T regulatory cells (Tregs) utilize in promoting corneal allograft survival.

Methods: : BALB/c mice bearing C57BL/6 corneas were injected with anti-IL-17A, anti-CD25 or a rat IgG isotype control antibody. CD4+CD25+ Tregs were isolated from graft acceptors and rejectors 3 weeks post transplantation. A CFSE-based suppression assay was used to assess the IL-17A requirement for Treg function by incubating Tregs with naïve CFSE-labeled CD4+ effector T cells in vitro with anti-CD3 antibody. Cytokine production from acceptor CD4+ T cell subsets was quantified by ELISA. Transwell assays were performed to test contact-dependent suppression. For blocking assays, antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor family-related gene ligand (GITRL) and transforming growth factor beta (TGFβ) 1, 2, 3 were used.

Results: : BALB/c mice rejected 50% of the C57BL/6 corneal allografts. Treatment with either anti-IL-17A or anti-CD25 antibody led to 90% and 100% rejection, respectively. In vivo and in vitro neutralization of IL-17A decreased the suppressive activity of Tregs by ~50-70%. Acceptor CD4+CD25- T cells selectively produced IL-17A. In transwell assays, contact-inhibition between the IL-17R expressing acceptor Tregs and CD4+ effector T cell responders led to ~80% loss in suppression. Acceptor Tregs treated in vitro with anti-IL-17A displayed a ≥2 fold decrease in CTLA-4, GITR and TGF-β1 expression by qPCR analysis. Simultaneous blockade of all three molecules in vitro impaired acceptor Treg-mediated suppression by ~50%. In vivo Treg activity was necessary only during the early phases following corneal transplantation as treatment with either anti-CD25 or anti-IL-17A did not affect the survival of corneal allografts if initiated 30 days following corneal transplantation.

Conclusions: : Maintenance of ocular immune privilege is mediated transiently by IL-17A and Tregs during initial establishment of the corneal allograft. Depletion of IL-17A impairs CD4+CD25+ Treg function by diminishing the expression of CTLA-4, GITR and membrane-bound TGF-β1.

Keywords: cornea: basic science • transplantation • immune tolerance/privilege 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×